Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study

BACKGROUND: Monoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM). In case of treatment failure of a CGRP pathway targeting mAb, physician has to decide whether using another anti-CGRP pathway mAb is useful. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Straube, Andreas, Broessner, Gregor, Gaul, Charly, Hamann, Xenia, Hipp, Joachim, Kraya, Torsten, Neeb, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207758/
https://www.ncbi.nlm.nih.gov/pubmed/37221478
http://dx.doi.org/10.1186/s10194-023-01593-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207758/
https://www.ncbi.nlm.nih.gov/pubmed/37221478
http://dx.doi.org/10.1186/s10194-023-01593-2

Ejemplares similares